All Stories

  1. A Novel Approach to Temperature Profiling in Relation to Clinical Outcomes in Oncological Patients with Neutropenia
  2. Características clínicas y epidemiológicas de las muertes por dengue durante un brote en el norte del Perú
  3. Immunocompromised Host Pneumonia: Definitions and Diagnostic Criteria: An Official American Thoracic Society Workshop Report
  4. Remdesivir and survival outcomes in critically ill patients with COVID-19: A multicentre observational cohort study
  5. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain
  6. Advances in molecular diagnostic tests for community-acquired pneumonia
  7. Machine-Learning Model for Mortality Prediction in Patients With Community-Acquired Pneumonia
  8. Estimating the risk of bacteraemia in hospitalised patients with pneumococcal pneumonia
  9. Host-targeted approaches to sepsis due to community-acquired pneumonia
  10. Respiratory viruses: their importance and lessons learned from COVID-19
  11. Early Recognition of Low-Risk SARS-CoV-2 Pneumonia
  12. Aspiration pneumonia
  13. Ceftaroline in severe community-acquired pneumonia
  14. Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
  15. Biomarcadores biológicos en las enfermedades respiratorias
  16. [Translated article] Biological Biomarkers in Respiratory Diseases
  17. What's Next in Pneumonia?
  18. Severe Infections Due to Respiratory Viruses
  19. Invasive pulmonary aspergillosis among intubated patients with SARS-CoV-2 or influenza pneumonia: a European multicenter comparative cohort study
  20. Management of pneumonia in critically ill patients
  21. COVID-19 in patients aged 80 years and over during the peaks of the first three pandemic waves at a Spanish tertiary hospital
  22. Impact on in-hospital mortality of ceftaroline versus standard of care in community-acquired pneumonia: a propensity-matched analysis
  23. Outcomes of Critically ill Very old patients with Acute Respiratory Distress Syndrome and Community-Acquired Pneumonia
  24. Impact on in-hospital mortality of Ceftaroline versus standard of care in Community-Acquired Pneumonia: A Propensity Matched Analysis
  25. The Value of C-Reactive Protein-to-Lymphocyte Ratio in Predicting the Severity of SARS-CoV-2 Pneumonia
  26. Prediction of ventilator-associated pneumonia outcomes according to the early microbiological response: a retrospective observational study
  27. Pulse oximetry is an essential tool that saves lives: a call for standardisation
  28. Predictive Performance of Risk Factors for Multidrug-Resistant Pathogens in Nosocomial Pneumonia
  29. Pneumonia
  30. Lymphopenia Is Associated With Poor Outcomes of Patients With Community-Acquired Pneumonia and Sepsis
  31. Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia
  32. PES Pathogens in Elderly Patients with Acquired Pneumonia in the Community
  33. Awareness and Pneumonia knowledge: where to start educating?
  34. Methicillin-susceptible Staphylococcus aureus in Community-Acquired Pneumonia: Risk Factors and Outcomes
  35. Systemic Inflammatory Response and Outcomes in Community-Acquired Pneumonia Patients Categorized According to the Smoking Habit or Presence of Chronic Obstructive Pulmonary Disease
  36. SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities
  37. Promoting the use of social networks in pneumonia
  38. Difficult to treat microorganisms in patients aged over 80 years with community-acquired pneumonia: the prevalence of PES pathogens
  39. Advances in molecular diagnostic tests for pneumonia
  40. Community-acquired pneumonia in critically ill very old patients: a growing problem
  41. Defining Community-Acquired Pneumonia as a Public Health Threat: Arguments in Favor from Spanish Investigators
  42. Can Artificial Intelligence Improve the Management of Pneumonia
  43. Reply to Musher
  44. Macrolide combination therapy for hospitalised CAP patients? An individualised approach supported by machine learning
  45. Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients
  46. Prevalence and risk factors of sepsis in very old patients with CAP
  47. Ventilator-Associated Pneumonia and PaO2/FIO2 Diagnostic Accuracy: Changing the Paradigm?
  48. non invasive diagnosis of nosocomial pneumonia
  49. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia
  50. Risk and Prognostic Factors in Very Old Patients with Sepsis Secondary to Community-Acquired pneumonia
  51. lymphopenia predicts mortality in patients with ICU pneumonia
  52. Addendum: Cillóniz, C.; Dominedò, C.; Nicolini, A.; Torres, A. PES Pathogens in Severe Community-Acquired Pneumonia. Microorganisms 2019, 7, 49
  53. Evaluation of the Magicplex™ Sepsis Real-Time Test for the Rapid Diagnosis of Bloodstream Infections in Adults
  54. Multidrug Resistant Gram-Negative Bacteria in Community-Acquired Pneumonia
  55. PES Pathogens in Severe Community-Acquired Pneumonia
  56. An international perspective on hospitalized patients with viral community-acquired pneumonia
  57. Early noninvasive ventilation treatment for respiratory failure due to severe community-acquired pneumonia
  58. Community-acquired pneumonia as an emergency condition
  59. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients with Community-Acquired Pneumonia
  60. Reply to Head and Keynan
  61. Drugs that increase the risk of community-acquired pneumonia: a narrative review
  62. Treating HIV-Positive/Non-AIDS Patients for Community-Acquired Pneumonia with ART
  63. Clinical Approach to Community-acquired Pneumonia
  64. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study
  65. Inflammatory response depends on time since onset of symptoms in pneumonia
  66. MagicplexTM Sepsis real-time test for the rapid diagnosis of bloodstream infections in adults
  67. Twenty-year trend in mortality among hospitalized patients with pneumococcal community-acquired pneumonia
  68. Burden and risk factors forPseudomonas aeruginosacommunity-acquired pneumonia: a multinational point prevalence study of hospitalised patients
  69. Community-acquired bacterial pneumonia in adult HIV-infected patients
  70. Microorganisms resistant to conventional antimicrobials in acute exacerbations of chronic obstructive pulmonary disease
  71. Community-acquired Pneumonia and Acute Respiratory Distress Syndrome
  72. Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging
  73. Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus–Infected Adult Patients: A Matched Case-Control Study
  74. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review
  75. Effectiveness of combination therapy versus monotherapy with a third-generation cephalosporin in bacteraemic pneumococcal pneumonia: A propensity score analysis
  76. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia
  77. Detection of human cytomegalovirus in bronchoalveolar lavage of intensive care unit patients
  78. Severe community-acquired pneumonia: Characteristics and prognostic factors in ventilated and non-ventilated patients
  79. New Sepsis Definition (Sepsis-3) and Community-acquired Pneumonia Mortality. A Validation and Clinical Decision-Making Study
  80. Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress
  81. Has Mortality of Community-Acquired Pneumonia Really Reduced?
  82. Predictors of treatment failure and clinical stability in patients with community acquired pneumonia
  83. Adjuvant therapies in critical care: steroids in community-acquired pneumonia
  84. Investigational drugs in phase I and phase II clinical trials for the treatment of community-acquired pneumonia
  85. Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality
  86. Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia
  87. The burden of PCV13 serotypes in hospitalized pneumococcal pneumonia in Spain using a novel urinary antigen detection test. CAPA study
  88. Time to blood culture positivity as a predictor of clinical outcomes and severity in adults with bacteremic pneumococcal pneumonia
  89. Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients
  90. Treatment with macrolides and glucocorticosteroids in severe community-acquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial
  91. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia
  92. Risk factors for community-acquired pneumonia in adults
  93. Antibiotic therapy prior to hospital admission is associated with reduced septic shock and need for mechanical ventilation in patients with community-acquired pneumonia
  94. Typical Presentation of Legionella pneumophila Community-Acquired Pneumonia
  95. Research in community-acquired pneumonia: the next steps
  96. Seasonality of pathogens causing community-acquired pneumonia
  97. Microbial Etiology of Pneumonia: Epidemiology, Diagnosis and Resistance Patterns
  98. Laboratory diagnosis of pneumonia in the molecular age
  99. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
  100. Clinical management of community acquired pneumonia in the elderly patient
  101. Community-Acquired Pneumonia 2000-2015: What is New?
  102. Response
  103. Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
  104. Community-acquired pneumonia related to intracellular pathogens
  105. Predictive and prognostic factors in patients with blood-culture-positive community-acquired pneumococcal pneumonia
  106. What is the clinical relevance of drug-resistant pneumococcus?
  107. Multilobar bilateral and unilateral chest radiograph involvement: implications for prognosis in hospitalised community-acquired pneumonia
  108. Pneumococcal vaccination
  109. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis
  110. Procalcitonin (PCT) levels for ruling-out bacterial coinfection in ICU patients with influenza: A CHAID decision-tree analysis
  111. Severe community-acquired pneumonia: Corticosteroids as adjunctive treatment to antibiotics
  112. Bronchiectasis in rare pulmonary diseases: A case series
  113. Bacteraemia in outpatients with community-acquired pneumonia
  114. Polymicrobial community-acquired pneumonia: An emerging entity
  115. Sensitivity, Specificity, and Positivity Predictors of the Pneumococcal Urinary Antigen Test in Community-Acquired Pneumonia
  116. Bacteraemia in outpatient with community-acquired pneumonia
  117. Ceftobiprole for the treatment of pneumonia: a European perspective
  118. Streptococcus pneumoniae-associated pneumonia complicated by purulent pericarditis: case series
  119. Microbiology and outcomes of community acquired pneumonia in non cystic-fibrosis bronchiectasis patients
  120. New antimicrobial approaches to gram positive respiratory infections
  121. Macrolide resistance and outcomes of patients with Streptococcus pneumoniae pneumonia.
  122. Risk Factors Associated with Potentially Antibiotic-Resistant Pathogens in Community-Acquired Pneumonia
  123. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis
  124. Severe community-acquired pneumonia: Severity and management
  125. Noninvasive ventilation for acute respiratory failure due to community-acquired pneumonia: A concise review and update
  126. Clinical Management of Bacterial Pneumonia
  127. Viral infections
  128. Detection of Pneumonia Associated Pathogens Using a Prototype Multiplexed Pneumonia Test in Hospitalized Patients with Severe Pneumonia
  129. Severity and outcomes of community acquired pneumonia in asthmatic patients
  130. Predicting treatment failure in patients with community acquired pneumonia: a case-control study
  131. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data
  132. Lung abscess due to Streptococcus pneumoniae: a case series and brief review of the literature
  133. Epidemiology, antibiotic therapy and clinical outcomes of healthcare-associated pneumonia in critically ill patients: a Spanish cohort study
  134. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome
  135. IgA level in plasma as a differential factor for influenza infection in severe viral pneumonia
  136. Pneumococcal disease: Epidemiology and new vaccines
  137. Community-acquired viral pneumonia in human immunodeficiency virus infected patients
  138. Phenotyping community-acquired pneumonia according to the presence of acute respiratory failure and severe sepsis
  139. Predicting Community-Acquired Pneumonia Etiology: Response
  140. A Worldwide Perspective of Nursing Home-Acquired Pneumonia Compared With Community-Acquired Pneumonia
  141. IgM levels in plasma predict outcome in severe pandemic influenza
  142. Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case–control study
  143. Impact of Age and Comorbidity on Cause and Outcome in Community-Acquired Pneumonia
  144. Multidrug-resistant pathogens in hospitalised patients coming from the community with pneumonia: a European perspective: Table 1
  145. Influence of Previous Use of Inhaled Corticoids on the Development of Pleural Effusion in Community-acquired Pneumonia
  146. Thrombocytosis Is a Marker of Poor Outcome in Community-Acquired Pneumonia
  147. Epidemiology, Clinical Features, and Prognosis of Elderly Adults with Severe Forms of Influenza A (H1N1)
  148. Systemic corticosteroids for community-acquired pneumonia: Reasons for use and lack of benefit on outcome
  149. Macrolide-based regimens in absence of bacterial co-infection in critically ill H1N1 patients with primary viral pneumonia
  150. Influenza A (H1N1) Pneumonia
  151. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes
  152. Invasive Pneumococcal Disease Today
  153. Bacterial co-infection with H1N1 infection in patients admitted with community acquired pneumonia
  154. Entendimento da mortalidade em pneumonia pneumocócica bacterêmica
  155. Cytokine Activation Patterns and Biomarkers Are Influenced by Microorganisms in Community-Acquired Pneumonia
  156. Pulmonary Complications Of Pneumococcal CAP: Incidence, Predictors, And Outcomes
  157. Corticosteroids In Community-Acquired Pneumonia: Therapeutic Reasons And Outcomes
  158. Influence Of Long-Term Use Of Inhaled Corticoids On The Development Of Pleural Effusion In Community Acquired Pneumonia
  159. Thrombocytosis Is A Diagnostic And Prognostic Marker In Community-Acquired Pneumonia
  160. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza
  161. Community-acquired pneumonia in outpatients: aetiology and outcomes
  162. CD4+ cell counts and HIV-RNA levels do not predict outcomes of community-acquired pneumonia in hospitalized HIV-infected patients
  163. CAP IN COPD PATIENTS
  164. Clinical relevance of mixed respiratory viral infections in adults with influenza A H1N1
  165. First influenza season after the 2009 pandemic influenza: report of the first 300 ICU admissions in Spain
  166. Microbial aetiology of community-acquired pneumonia and its relation to severity
  167. Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
  168. Pandemic and post-pandemic Influenza A (H1N1) infection in critically ill patients
  169. Influenza pneumonia: a comparison between seasonal influenza virus and the H1N1 pandemic
  170. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia
  171. Severe Mixed Community Acquired Pneumoniae
  172. Community-acquired Pneumonia In Outpatients: Microbial Etiology
  173. INDICATION OF PLEURAL DRAINAGE IN PARAPNEUMONIC EFFUSION: ADHERENCE TO THE AMERICAN COLLEGE OF CHEST PHYSICIANS’ GUIDELINES
  174. PARAPNEUMONIC EFFUSIONS ACCORDING TO THE CLASSIFICATION OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS: CLINICAL CHARACTERISTICS
  175. Healthcare-associated Pneumonia (HCAP): Clinical Features And Biomarkers
  176. Nursing home-acquired pneumonia: a 10 year single-centre experience
  177. Impact of Smoking Habit on the Etiology of Community-Acquired Pneumonia (CAP).
  178. Community-Acquired Pneumonia: Etiology and Severity Scores.
  179. Complicated Pneumococcal Pneumonia in Adults.
  180. Severe community-acquired pneumonia